BioSpace News Archive

Ironwood Pharmaceuticals to Present New Data on Once-Weekly Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) at Digestive Disease Week ® 2024.

MDxHealth SA announced its financial results for the first quarter ended March 31, 2024 and the closing of a new debt facility with OrbiMed.

Avadel Pharmaceuticals plc announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company’s financial results for the first quarter ended March 31, 2024.

Editas Medicine, Inc. today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases.

Denali Therapeutics Inc. today announced that the Sean M. Healey & AMG Center in collaboration with the Northeast ALS Consortium (NEALS) completed enrollment for Regimen G of the Phase 2/3 HEALEY ALS Platform Trial.

Amicus Therapeutics announced that the Company will host a conference call and live audio webcast on Thursday, May 9, 2024, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2024.

TG Therapeutics, Inc. announced its financial results for the first quarter of 2024, along with recent company developments.

Beyond Cancer, Ltd. announced being selected to present on the clinical development program of its Ultra-High Concentration Nitric Oxide at the upcoming American Society of Clinical Oncology Annual Meeting taking place May 31 – June 4, 2024 at the McCormick Place Convention Center in Chicago, Illinois.

Amarin Corporation plc, provided an update on the Company’s business highlights and announced financial results for the quarter ended March 31, 2024.

Barinthus Biotherapeutics plc, formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, announced the appointment of Leon Hooftman, M.D., as Chief Medical Officer.